Papyrus Therapeutics Inc Announces Additions to Its Board of Directors mychesco.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mychesco.com Daily Mail and Mail on Sunday newspapers.
WEST CHESTER, Pa. (BUSINESS WIRE) Papyrus Therapeutics Inc. is delighted to announce that two new members have joined our Board of Directors, Marc Beer as chairman and Professor James Lorens PhD as an independent director.Marc brings more then 30 years of therapeutic development and commercialization experience in.
I am truly proud of the Group s achievements over the period. We not only secured major new partnerships, brought the Oxbox manufacturing facility online in record time and responded to the challenges of the pandemic, but the team has also been able to rapidly work with AstraZeneca to provide a vaccine solution for COVID-19. This is a true testament to the world-class calibre and dedication of our staff in the year that the Group also gained entry to the FTSE250. Looking to the future, with the continued tide of growth in cell and gene therapy, coupled with the Group s leadership position in the lentiviral vector field, we are well positioned to advance both our own proprietary pipeline and that of our current and future partners programmes.
Targovax and Papyrus Therapeutics enter research collaboration to develop novel ONCOS viruses with receptor tyrosine kinase (RTK) inhibitor functionality
- The parties will explore the feasibility and effect of combining their respective oncolytic virus and receptor tyrosine kinase (RTK) inhibitor technologies
- Targovax retains the right to develop and commercialize novel drug candidates emerging from the pre-clinical collaboration
News provided by
Share this article
OSLO, Norway, Feb. 10, 2021 /PRNewswire/
Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that it has entered into a research collaboration agreement with Papyrus Therapeutics to assess the potential of combining their respective proprietary technology platforms to develop a first-in-class oncolytic virus concept with RTK inhibitor functionality.